Snapshot from Aug 16, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / FDA accepts Camurus NDA resubmission...
Regulatory regulatory submission

FDA accepts Camurus NDA resubmission for CAM2029

Analysis based on 7 articles · First reported Jul 17, 2026 · Last updated Jul 21, 2026

Sentiment
40
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The FDA acceptance of the resubmission removes a key regulatory overhang for Camurus, potentially boosting investor confidence. If approved by the December PDUFA date, CAM2029 could capture a significant share of the US acromegaly market, driving revenue growth.

biotechnology pharmaceutical
Event Summary

Camurus announced that the US FDA has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029 (octreotide extended-release injection) for the treatment of acromegaly. The FDA assigned a PDUFA target action date of December 18, 2026. The resubmission follows a Complete Response Letter (CRL) issued on June 10, 2026, related to cGMP observations at a third-party manufacturer, with no concerns regarding safety or efficacy. The contract manufacturer has implemented remediation actions and confirmed inspection readiness. CAM2029 is already approved in the EU and UK under the brand name Oczyesa.

Entities Involved
stock
Camurus
Camurus is the sponsor of the NDA; acceptance for review is a positive step toward US approval, which would expand its market for CAM2029.
Importance 100.0 Sentiment 60.0
govactor
United States — Food and Drug Administration
The FDA accepted the resubmission for review and set a PDUFA date; its regulatory decision will determine market access for CAM2029 in the US.
Importance 80.0 Sentiment 0.0
cnt
United States
The US is the target market for the NDA; approval would make CAM2029 available to US patients with acromegaly.
Importance 50.0 Sentiment 0.0
per
Fredrik Tiberg
As President & CEO of Camurus, Fredrik Tiberg commented on the collaboration with the FDA; his role is primarily representational.
Importance 20.0 Sentiment 0.0
alliance
European Union
The EU has already granted marketing authorization for CAM2029 (Oczyesa), providing a reference for the US review.
Importance 10.0 Sentiment 0.0
cnt
United Kingdom
The UK has already granted marketing authorization for CAM2029 (Oczyesa), providing a reference for the US review.
Importance 10.0 Sentiment 0.0
cnt
Sweden
Sweden is the headquarters of Camurus; the event has minimal direct impact on the country.
Importance 5.0 Sentiment 0.0
per
Fredrik Joabsson
As Chief Business Development Officer, Fredrik Joabsson is a contact for investor relations; his role is peripheral to the event.
Importance 5.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States
United States — Food and Drug Administration related ↔ European Union
United States — Food and Drug Administration related ↔ United Kingdom
United States related ↔ European Union
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
United States related ↔ Sweden
European Union related ↔ United Kingdom
European Union related ↔ Sweden
United Kingdom related ↔ Sweden
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.